Literature DB >> 15066645

Clinical management of immunocompetent hospitalized patients with community-acquired pneumonia.

Olivier Lamy1, Guy Van Melle, Jacques Cornuz, Bernard Burnand.   

Abstract

Background: Clinical practices and guidelines may differ regarding the management of inpatients with community-acquired pneumonia (CAP).
Methods: The management of 152 consecutive CAP inpatients (70+/-17 years) admitted to a teaching hospital was analyzed retrospectively and compared with published data and an evidence-based guideline developed at our institution.
Results: Of the patients studied, 64% had a high prognostic score index (PSI), 14% were admitted to the ICU, and 4.6% died. Initially, patients received either a one-drug (47%) or a two-drug (53%) antibiotic regimen. None of the 20 PSI parameters, and neither the PSI nor admission to the ICU, was associated with the initial antibiotic regimen. Agreement between current practice and our guideline was low (kappa=0.16). Following the recommendations would have led to a decrease of 51% in the initial two-drug regimen. The duration of i.v. antibiotherapy was higher in patients following the two-drug regimen (142+/-150 vs. 102+/-60 h, P<0.05). Chest physiotherapy (CP) and bronchodilatators (BD) were prescribed in 72% and 54% of cases, respectively (median duration 10 days). Conclusions: The variations observed in the clinical management of CAP inpatients were not in agreement with published guidelines. The overuse of a two-drug regimen, CP, and BD necessitates the development and implementation of evidence-based guidelines proposing detailed steps for the management of CAP inpatients.

Entities:  

Year:  2004        PMID: 15066645     DOI: 10.1016/j.ejim.2003.11.003

Source DB:  PubMed          Journal:  Eur J Intern Med        ISSN: 0953-6205            Impact factor:   4.487


  6 in total

Review 1.  Severity assessment tools to guide ICU admission in community-acquired pneumonia: systematic review and meta-analysis.

Authors:  James D Chalmers; Pallavi Mandal; Aran Singanayagam; Ahsan R Akram; Gourab Choudhury; Philip M Short; Adam T Hill
Journal:  Intensive Care Med       Date:  2011-06-10       Impact factor: 17.440

2.  Macrolide use in the treatment of critically ill patients with pneumonia: Incidence, correlates, timing and outcomes.

Authors:  Wendy I Sligl; Holly Hoang; Dean T Eurich; Atul Malhotra; Thomas J Marrie; Sumit R Majumdar
Journal:  Can J Infect Dis Med Microbiol       Date:  2013       Impact factor: 2.471

3.  The International Community-Acquired Pneumonia (CAP) Collaboration Cohort (ICCC) study: rationale, design and description of study cohorts and patients.

Authors:  Phyo Kyaw Myint; Chun Shing Kwok; Sumit R Majumdar; Dean T Eurich; Allan B Clark; Pedro P España; Shin Yan Man; David T Huang; Donald M Yealy; Derek C Angus; Alberto Capelastegui; Timothy H Rainer; Thomas J Marrie; Michael J Fine; Yoon K Loke
Journal:  BMJ Open       Date:  2012-05-21       Impact factor: 2.692

Review 4.  Severe community-acquired pneumonia.

Authors:  Wendy I Sligl; Thomas J Marrie
Journal:  Crit Care Clin       Date:  2013-07       Impact factor: 3.598

Review 5.  Prediction of severe community-acquired pneumonia: a systematic review and meta-analysis.

Authors:  Christophe Marti; Nicolas Garin; Olivier Grosgurin; Antoine Poncet; Christophe Combescure; Sebastian Carballo; Arnaud Perrier
Journal:  Crit Care       Date:  2012-07-27       Impact factor: 9.097

6.  Prognostic performance of MR-pro-adrenomedullin in patients with community acquired pneumonia in the Emergency Department compared to clinical severity scores PSI and CURB.

Authors:  Jacopo Maria Legramante; Maria Mastropasqua; Beniamino Susi; Ottavia Porzio; Marta Mazza; Grazia Miranda Agrippino; Cartesio D Agostini; Antonella Brandi; Germano Giovagnoli; Vito Nicola Di Lecce; Sergio Bernardini; Marilena Minieri
Journal:  PLoS One       Date:  2017-11-21       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.